{
    "nctId": "NCT01212887",
    "briefTitle": "Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer",
    "officialTitle": "A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Percentage of patients (goal is 50%) who are evaluable for MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed malignancy\n\n  * Metastatic or unresectable disease\n  * Standard curative or palliative measures do not exist, are no longer effective, have been completed, or have been refused\n* CEA-positive tumor (either by immunohistochemistry or as demonstrated by elevated CEA \\> 50 \u03bcg/L)\n* No primary brain tumor or brain metastases\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0-1\n* Life expectancy \u2265 3 months\n* Hemoglobin \u2265 10 g/dL\n* Platelet count \u2265 100 x 10\\^9/L\n* Neutrophil count \u2265 2.0 x 10\\^9/L\n* Lymphocyte count \u2265 1.0 x 10\\^9/L\n* Serum bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* ALT/AST \u2264 5 times ULN\n* Alkaline phosphatase \u2264 5 times ULN\n* Calculated creatinine clearance OR isotope clearance measurement \u2265 50 mL/min\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy (male patients must use barrier-method contraception)\n* LVEF \u2265 50% on MUGA scan (for patients receiving cyclophosphamide)\n* ECG and exercise ECG (or stress ECHO) normal (may be abnormal but not clinically significant)\n* Urine dipstick normal (may be abnormal but not clinically significant)\n* No medical high risk due to nonmalignant systemic disease including active uncontrolled infection\n* No known serologically positive hepatitis B, hepatitis C, HIV, or HTLV\n* No history of autoimmune disease\n* No inflammatory bowel disease\n* No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac disease\n* No concurrent malignancies originating from other primary sites, except for adequately treated cone-biopsied carcinoma in situ of the cervix uteri or basal cell or squamous cell carcinoma of the skin\n* No other condition that, in the investigator's opinion, would make the patient an unsuitable candidate for the clinical trial\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 30 days since prior and no concurrent participation in another clinical trial\n* At least 4 weeks since prior and no concurrent radiotherapy (except for palliative reasons \\[i.e., control of bone pain\\])\n* At least 4 weeks since prior and no concurrent endocrine therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)\n* No toxic manifestations of previous treatment, except for alopecia or certain grade 1 toxicities that, in the opinion of the investigator and CRUK (Cancer Research UK), would exclude the patient (e.g., grade 1 neuropathy or grade 1 fatigue)\n* No prior major thoracic and/or abdominal surgery from which the patient has not yet recovered\n* No prior bone marrow transplant or extensive radiotherapy to \\> 25% of bone marrow\n* No concurrent systemic steroids or other immunosuppressive therapy\n* No other concurrent anticancer therapy or investigational drugs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}